Premier Alternatives

Illuminare Biotechnologies

New York, NY · Founded 2016 · Privately Held (backing)

Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage. Illuminare Biotechnologies is based in New York, NY and was founded in 2016. Its last reported valuation was $11.4 million in Aug 2017. It has raised $7.1 million across 1 recorded round; the latest was a $3.6 million seed round in May 2026.

Last reported valuation
$11.4M
Oct 2026
Priced at
—
Total raised
$7.1M
Last round
Seed Round
May 2026

Illuminare Biotechnologies key facts

as of Oct 2026
  • Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage.
  • Illuminare Biotechnologies is valued at approximately $11.4M as of Oct 2026 (last reported valuation).
  • It has raised $7.1M across 1 recorded rounds; the latest was Seed Round ($3.6M) in May 2026.
  • Notable investors include Memorial Sloan Kettering Cancer Center, Endo Investors, GE Aerospace, Thylacine Capital.
  • 1 institutional filer reports fund marks on Illuminare Biotechnologies across 2 filings.
  • Illuminare Biotechnologies has filed 1 Form D with the SEC, most recently Dec 2018 ( sold).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$11.4M

Illuminare Biotechnologies's last reported valuation, Aug 2017. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Illuminare Biotechnologies with a free account
  • ·Watch Illuminare Biotechnologies: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Illuminare Biotechnologies

1 filers · latest Mar 2026

1 SEC-registered fund reported 2 fair-value marks on Illuminare Biotechnologies between Dec 2025 and Mar 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 2 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Illuminare Biotechnologies funding rounds

1 rounds
May 2026Seed Round$3.6MSEC filing▮
Full funding history →

Illuminare Biotechnologies valuation

Illuminare Biotechnologies's last reported valuation was $11.4 million in Aug 2017. No priced round, secondary trade or fund mark has surfaced since.

How much has Illuminare Biotechnologies raised?

Illuminare Biotechnologies has raised $7.1 million in total; 1 of its rounds is on record. The largest on record was a $3.6 million seed round in May 2026.

Illuminare Biotechnologies has filed 1 Form D with the SEC, most recently in Dec 2018 (null sold).

Institutional holders and vehicles

1 SEC-registered fund reported 2 fair-value marks on Illuminare Biotechnologies between Dec 2025 and Mar 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Illuminare Biotechnologies investors

4 investors are on record for Illuminare Biotechnologies, including Memorial Sloan Kettering Cancer Center, Endo Investors, GE Aerospace and Thylacine Capital. The seed round in May 2026 drew 42 investors.

About Illuminare Biotechnologies

Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage. The company's technology binds specifically to myelin and illuminates to make nerves, fat, muscles, and blood vessels more visible, enabling surgeons with improved visibility during operations.

Sector
Healthcare
HQ
New York, NY, United States
Founded
2016
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.